CUE News and Press, Cue Biopharma Inc. From 04/08/24

2024-04-08 21:43:09 ET Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Conference Call April 08, 2024, 16:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Mi...

2024-04-08 17:44:34 ET More on Cue Biopharma Jefferies starts Cue at buy, cites partnering potential Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma Read the ful...

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. ...

2024-04-07 17:35:23 ET CUE For Seeking Alpha's full earnings season calendar, click here . Read the full article on Seeking Alpha For further details see: Notable earnings after Monday's close

2024-04-02 13:53:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ: CUE ) just reported results for the fourth quarter of 2023. Cue Biopharma reported earnings per share of -29 cents. This was below the analyst estim...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

2024-03-13 14:55:38 ET More on Cue Biopharma Cue Biopharma: Not Exactly Sinking The Money Ball Yet Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma Read the full ...

Cue Biopharma, Inc. (NASDAQ: CUE) is one of today's top gainers. The company's shares have moved 19.77% on the day to $2.12. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of canc...

2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...